Under the deal, IGM will carry out the clinical testing of imvotamab plus Zynlonta to treat relapsed/refractory B cell non-Hodgkin’s lymphoma. Credit: National Cancer Institute on Unsplash.

IGM Biosciences has signed a clinical trial partnership and supply agreement with ADC Therapeutics to analyse the combination of imvotamab and Zynlonta (loncastuximab tesirine-lpyl) to treat relapsed/refractory (R/R) B cell non-Hodgkin’s lymphoma (NHL).

Imvotamab is an IgM-based CD20 x CD3 T cell engaging bispecific antibody of IGM while Zynlonta is a CD19-directed antibody-drug conjugate (ADC) of ADC Therapeutics.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As per the deal, IGM will carry out clinical testing to assess the safety and efficacy of imvotamab plus Zynlonta to treat R/R NHL patients. 

ADC Therapeutics will offer the clinical capabilities of Zynlonta and will deliver the drug to back the trial. 

IGM plans to commence the trial in the first quarter of next year. 

See Also:

Favourable mechanistic rationale and preclinical findings indicating robust activity of the combination therapy are the basis for this clinical partnership.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

IGM Biosciences chief medical officer Chris Takimoto said: “Patients with B cell non-Hodgkin’s lymphoma are in need of efficacious and well-tolerated treatments. 

“We are excited to enter this collaboration with ADC Therapeutics that aims to provide a novel combination regimen targeting both CD19- and CD20-expressing cells for patients with relapsed/refractory B cell non-Hodgkin’s lymphoma. 

“We look forward to working with the team at ADC Therapeutics and initiating clinical testing in the first quarter of 2023.”

Zynlonta received US Food and Drug Administration (FDA) approval for treating adults with R/R large B-cell lymphoma following two or more lines of systemic therapy.

An Imvotamab 100mg dose had demonstrated a 50% complete response rate. 

Cytokine release syndrome was observed in under 20% of the 28 subjects who received the treatment in the titration dosing cohorts as per data that was reported last year.

In March this year, IGM and Sanofi signed an exclusive worldwide collaboration agreement to create, develop, produce, and commercialise IgM antibody agonists for oncology, immunology, and inflammation targets.